The safety of calcium-channel blockers

Clinical Cardiology

Volumn 21, Issue 12 SUPPL. 2, 1998, Pages

  Massie, Barry M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NIFEDIPINE; VERAPAMIL;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DRUG SAFETY; DRUG USE; HEART INFARCTION; HUMAN; TREATMENT INDICATION;

ANGINA PECTORIS; CALCIUM CHANNEL BLOCKERS; HUMANS; HYPERTENSION; MYOCARDIAL INFARCTION; RISK FACTORS;

EID: 3743102793     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (32)

1. Neaton J, Grimm R, Prineas R, Stamler J, Grandits G, Elmer P, Cutler J, Flack J, Schoenberger J, McDonald R, Lewis C, Liebson P: Treatment of mild hypertension study: Final results. J Am Med Assoc 1993;270(6):713-724
2. Frishman WH: Current status of calcium channel blockers. Curr Probl Cardiol 1994;19(11):639-688
3. Materson BJ, Rede DJ, Cushman WC, Massie BM, Freis ED, Kochar MS, Hamburger RJ, Fye C, Lakshman R, Gottdiener J: Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veteran Affairs Cooperative Study Group On Antihypertensive Agents. N Engl J Med 1993;328(13):914-921
4. Straka RJ, Swanson AL, Parra D: Calcium channel antagonists: Morbidity and mortality - what's the evidence? Am Fam Phys 1998;57(7):1551-1560
5. Psaty B, Heckbert S, Koepsell T, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD: The risk of MI associated with antihypertensive drug therapies. J Am Med Assoc 1995;247(8):620-625
6. Furberg CD, Psaty BM, Meyer JV: Nifedipine. Dose-related increase in mortality in patients with coronary artery disease. Circulation 1995;92(5):1326-1331
7. Pahor M, Guralnik JM, Corti M, Foley DJ, Carbonin P, Havlik RJ: Long-term survival and use of antihypertensive medications in older persons. J Am Ger Soc 1995;43(11):1191-1197
8. Epstein M: Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995; 155(20):2150-2156
9. Roine RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S: Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. J Am Med Assoc 1990;264(24):3171-3177
10. Bigger JT Jr, Coromilas J, Roinitzky LM, Fleiss JL, Kleiger RE, and the Multicenter Diltiazem Postinfarction Trial Investigators: Effect of diltiazem on cardiac rate and rhythm after MI. Am J Cardiol 1989;63:172-176
11. Egstrup K, Andersen PE: Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison to metoprolol. Am J Cardiol 1993;71(12):177-183
12. Pool PE: The clinical significance of neurohormonal activation. Clin Ther 1997;19(suppl A):53-73
13. Alderman MH, Cohen H, Roque R, Madhavan S: Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997;349(9052):594-598
14. Jick H, Vasilakis C, Derby LE: Antihypertensive drugs and fatal myocardial infarction in persons with uncomplicated hypertension. Epidemiology 1997;8(14):446-448
15. Braun S, Boyko V, Behar S, Reicher-Reiss H, Shotan A, Schlessinger Z, Rosenfeld T, Palant A, Friedensohn A, Laniado S, Goldbourt U: Calcium antagonists and mortality in patients with coronary artery disease: A cohort study of 11,575 patients. J Am Coll Cardiol 1996;28(1):7-11
16. Messerli FH, Boden WE, Fischer Hansen J, Schechtman KB: Heart rate lowering antagonists in hypertensive post MI patients. J Am Coll Cardiol 1996;27(2):178A
17. Packer M: The PRAISE trial (Prospective Randomized Amlodipine Survival Evaluation): Background and main results. Presented at the American College of Cardiology Annual Meeting, New Orleans, La., March 1995
18. Lewis BS: Calcium antagonists in patients with left ventricular dysfunction: Back on the bridge? J Cardiol Fail 1996;2(4 suppl): S259-S265
19. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Page V, Ghadinan P, LeLorier J, Hamet P: Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996;14(10):1237-1245
20. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, deLeeuw PW, Dollery CT, Fletcher AE, Foretter F, Leonitti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A: Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350:757-764
21. SHEP Cooperative Research Group: Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). J Am Med Assoc 1991;265:3255-3264
22. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff MS, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338(10):645-652
23. Bakris G, White D: Effects of an ACE inhibitor combined with a calcium channel blocker on progression of diabetic nephropathy. J Hum Hypertens 1997;11(01):35-38
24. Toggle DJ: Pharmacologic and therapeutic differences among calcium channel antagonists: Profile of mibefradil, a new calcium antagonist. Am J Cardiol 1996; 78(suppl 9A):7-12
25. Katz AM: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996;28(2):522-529
26. 2+ channel blocker Ro 40-5967, which binds to the [3H] desmethoxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990;4(3):731-736
27. Cremers B, Flesch M, Sudkamp M, Bohm M: Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil. J Cardiovasc Pharmacol 1997;29(5):692-696
28. 2+ inward currents by Ro 40-5967 and verapamil: Relation to negative inotropy. Eur. J Pharmacol 1991;196(2):205-207
29. Mulder P, Richard V, Compagnon P, Henry J, Lallemand F, Clozel J, Koen R, Mace B, Thuillez C: Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure. J Am Coll Cardiol 1997;29(2):416-421
30. Massie BM: Mibefradil: A selective T-type calcium antagonist. Am J Cardiol 1997;80(9A):23I-32I
31. Massie BM, Lacourcière Y, Viskoper R, Woittiez A, Kobrin I: Mibefradil in the treatment of systemic hypertension: Comparative studies with other calcium antagonists. Am J Cardiol 1997; 80(4B):27C-33C
32. Ernst ME, Kelly MW: Mibefradil, a pharmacologically distinct calcium antagonist. Pharmacotherapy 1998;18(3):463-485